EPS for Arbutus Biopharma Corp (ABUS) Expected At $-0.38

October 14, 2017 - By Nellie Frank

 EPS for Arbutus Biopharma Corp (ABUS) Expected At $ 0.38

Wall Street await Arbutus Biopharma Corp (NASDAQ:ABUS) to release earnings on November, 2. Analysts forecast EPS of $-0.38, down exactly $0.07 or 22.58 % from 2014’s $-0.31 EPS. After posting $-0.28 EPS for the previous quarter, Arbutus Biopharma Corp’s analysts now forecast 35.71 % negative EPS growth. The stock decreased 2.03% or $0.15 during the last trading session, reaching $7.25. About 235,125 shares traded. Arbutus Biopharma Corp (NASDAQ:ABUS) has declined 2.31% since October 14, 2016 and is downtrending. It has underperformed by 19.01% the S&P500.

Arbutus Biopharma Corp (NASDAQ:ABUS) Ratings Coverage

Among 5 analysts covering Arbutus Biopharma (NASDAQ:ABUS), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Arbutus Biopharma had 15 analyst reports since August 7, 2015 according to SRatingsIntel. The company was initiated on Friday, August 7 by Wedbush. As per Wednesday, November 30, the company rating was upgraded by Chardan Capital Markets. The stock has “Outperform” rating by RBC Capital Markets on Friday, November 6. The firm has “Buy” rating by Chardan Capital Markets given on Friday, August 4. Chardan Capital Markets downgraded Arbutus Biopharma Corp (NASDAQ:ABUS) rating on Tuesday, December 13. Chardan Capital Markets has “Neutral” rating and $3 target. The stock has “Sell” rating by Chardan Capital Markets on Monday, May 16. The company was initiated on Wednesday, September 2 by JMP Securities. The stock of Arbutus Biopharma Corp (NASDAQ:ABUS) has “Market Perform” rating given on Friday, August 5 by Leerink Swann. The rating was upgraded by Chardan Capital Markets on Tuesday, April 4 to “Buy”. The stock of Arbutus Biopharma Corp (NASDAQ:ABUS) has “Outperform” rating given on Wednesday, February 1 by Wedbush.

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The company has market cap of $398.95 million. The Firm is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection , a disease of the liver caused by the hepatitis B virus (HBV). It currently has negative earnings. It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology.

More notable recent Arbutus Biopharma Corp (NASDAQ:ABUS) news were published by: Nasdaq.com which released: “Company Spotlight: Arbutus Biopharma” on September 15, 2017, also Seekingalpha.com with their article: “Arbutus Biopharma: Updates To Thesis” published on September 18, 2017, Streetinsider.com published: “Form 8-K Arbutus Biopharma Corp For: Oct 02” on October 03, 2017. More interesting news about Arbutus Biopharma Corp (NASDAQ:ABUS) were released by: Nasdaq.com and their article: “Arbutus to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference” published on September 25, 2017 as well as Seekingalpha.com‘s news article titled: “Trading Arbutus After Phase 2 Data: Part 2” with publication date: September 26, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com